ebv gp350-ferritin vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 7, 2021 (NCT04645147)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human herpesvirus 4Immunity, active
Human herpesvirus 4 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06908096 | Phase 1 | May 29, 2025 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05683834 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04645147 | Phase 1 | Dec 7, 2021 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1